FDA sidesteps MDMA controversy at PTSD meeting, but public pushes back

Critics addressed the elephant in the room during the FDA’s first public meeting on trauma since its decision to delay MDMA-assisted therapy approval.

The post FDA sidesteps MDMA controversy at PTSD meeting, but public pushes back appeared first on Green Market Report.